{"schema_version":"secwatch.filing_event.v1","accession":"0001607062-21-000309","form_type":"8-K/A","ticker":"RGBP","cik":"0001589150","company_name":"Regen BioPharma Inc","filed_at":"2021-08-31T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.701941+00:00","generated_at":"2026-06-29T06:45:39.551607+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"medium","headline":"Regen Biopharma corrects convertible debt date, becomes current on SEC filings, plans to settle notes","bullets":["Corrects earlier statement: no convertible debt issued since July 2019, not July 2020.","Company is no longer delinquent in SEC reporting as of August 27, 2021 10-Q filing.","Intends to negotiate settlement of remaining convertible notes to reduce or eliminate dilution, no assurance given."],"urls":{"canonical":"https://secwatch.observer/filing/0001607062-21-000309","json":"https://secwatch.observer/filing/0001607062-21-000309.json","markdown":"https://secwatch.observer/filing/0001607062-21-000309.md","text":"https://secwatch.observer/filing/0001607062-21-000309.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1589150/000160706221000309/0001607062-21-000309-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1589150/000160706221000309/rgbp083121form8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T06:45:39.551607+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}